Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays

Science Signaling

Volumn 8, Issue 359, 2015, Pages

  Smith, Matthew A ^a   Hall, Richard ^a   Fisher, Kate ^a   Haake, Scott M ^a   Khalil, Farah ^a   Schabath, Matthew B ^a   Vuaroqueaux, Vincent ^b   Fiebig, Heinz Herbert ^b   Altiok, Soner ^a   Chen, Yian Ann ^a   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b CHARLES RIVER LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MONOCLONAL ANTIBODY; MULTIPROTEIN COMPLEX; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSAY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; COMPLEX FORMATION; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; PROXIMITY LIGATION ASSAY; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; EVALUATION STUDY; GENETICS; IMMUNOASSAY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PROTEIN ANALYSIS; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS, TUMOR; CELL LINE, TUMOR; CETUXIMAB; GRB2 ADAPTOR PROTEIN; HETEROGRAFTS; HUMANS; IMMUNOASSAY; LUNG NEOPLASMS; MICE; MULTIPROTEIN COMPLEXES; PROTEIN INTERACTION MAPPING; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84920964526     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005906     Document Type: Article

References (52)

1. T. R. Wilson, J. Fridlyand, Y. Yan, E. Penuel, L. Burton, E. Chan, J. Peng, E. Lin, Y. Wang, J. Sosman, A. Ribas, J. Li, J. Moffat, D. P. Sutherlin, H. Koeppen, M. Merchant, R. Neve, J. Settleman, Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509 (2012).
2. F. Harbinski, V. J. Craig, S. Sanghavi, D. Jeffery, L. Liu, K. A. Sheppard, S. Wagner, C. Stamm, A. Buness, C. Chatenay-Rivauday, Y. Yao, F. He, C. X. Lu, V. Guagnano, T. Metz, P. M. Finan, F. Hofmann, W. R. Sellers, J. A. Porter, V. E. Myer, D. Graus-Porta, C. J. Wilson, A. Buckler, R. Tiedt, Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth. Cancer Discov. 2, 948-959 (2012).
3. R. Straussman, T. Morikawa, K. Shee, M. Barzily-Rokni, Z. R. Qian, J. Du, A. Davis, M. M. Mongare, J. Gould, D. T. Frederick, Z. A. Cooper, P. B. Chapman, D. B. Solit, A. Ribas, R. S. Lo, K. T. Flaherty, S. Ogino, J. A. Wargo, T. R. Golub, Tumour microenvironment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504 (2012).
4. F. R. Hirsch, P. A. Jänne, W. E. Eberhardt, F. Cappuzzo, N. Thatcher, R. Pirker, H. Choy, E. S. Kim, L. Paz-Ares, D. R. Gandara, Y. L. Wu, M. J. Ahn, T. Mitsudomi, F. A. Shepherd, T. S. Mok, Epidermal growth factor receptor inhibition in lung cancer: Status 2012. J. Thorac. Oncol. 8, 373-384 (2013).
5. S. Misale, F. Di Nicolantonio, A. Sartore-Bianchi, S. Siena, A. Bardelli, Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Discov. 4, 1269-1280 (2014).
6. C. Boeckx, M. Baay, A. Wouters, P. Specenier, J. B. Vermorken, M. Peeters, F. Lardon, Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: Focus on potential molecular mechanisms of drug resistance. Oncologist 18, 850-864 (2013).
7. F. M. Sirotnak, M. F. Zakowski, V. A. Miller, H. I. Scher, M. G. Kris, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885-4892 (2000).
8. M. Hidalgo, L. L. Siu, J. Nemunaitis, J. Rizzo, L. A. Hammond, C. Takimoto, S. G. Eckhardt, A. Tolcher, C. D. Britten, L. Denis, K. Ferrante, D. D. Von Hoff, S. Silberman, E. K. Rowinsky, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001).
9. N. I. Goldstein, M. Prewett, K. Zuklys, P. Rockwell, J. Mendelsohn, Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1, 1311-1318 (1995).
10. E. J. Lowenstein, R. J. Daly, A. G. Batzer, W. Li, B. Margolis, R. Lammers, A. Ullrich, E. Y. Skolnik, D. Bar-Sagi, J. Schlessinger, The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling. Cell 70, 431-442 (1992).
11. J. Li, K. Bennett, A. Stukalov, B. Fang, G. Zhang, T. Yoshida, I. Okamoto, J. Y. Kim, L. Song, Y. Bai, X. Qian, B. Rawal, M. Schell, F. Grebien, G. Winter, U. Rix, S. Eschrich, J. Colinge, J. Koomen, G. Superti-Furga, E. B. Haura, Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol. Syst. Biol. 9, 705 (2013).
12. P. K. Tan, J. Wang, P. L. Littler, K. K. Wong, T. A. Sweetnam, W. Keefe, N. R. Nash, E. C. Reding, F. Piu, M. R. Brann, H. H. Schiffer, Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer. Mol. Pharmacol. 72, 1440-1446 (2007).
13. F. Koizumi, T. Shimoyama, F. Taguchi, N. Saijo, K. Nishio, Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. Int. J. Cancer 116, 36-44 (2005).
14. R. Pirker, J. R. Pereira, J. Von Pawel, M. Krzakowski, R. Ramlau, K. Park, F. De Marinis, W. E. Eberhardt, L. Paz-Ares, S. Störkel, K. M. Schumacher, A. Von Heydebreck, I. Celik, K. J. O'Byrne, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol. 13, 33-42 (2012).
15. J. Mazières, W. Brugger, F. Cappuzzo, P. Middel, A. Frosch, I. Bara, G. Klingelschmitt, B. Klughammer, Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study. Lung Cancer 82, 231-237 (2013).
16. R. L. Camp, G. G. Chung, D. L Rimm, Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat. Med. 8, 1323-1327 (2002).
17. C. Mascaux, M. W. Wynes, Y. Kato, C. Tran, B. R. Asuncion, J. M. Zhao, M. Gustavson, J. Ranger-Moore, F. Gaire, J. Matsubayashi, T. Nagao, K. Yoshida, T. Ohira, N. Ikeda, F. R. Hirsch, EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor-A novel antibody for immunohistochemistry or AQUA technology. Clin. Cancer Res. 17, 7796-7807 (2011).
18. O. Söderberg, M. Gullberg, M. Jarvius, K. Ridderstråle, K. J. Leuchowius, J. Jarvius, K. Wester, P. Hydbring, F. Bahram, L. G. Larsson, U. Landegren, Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods 3, 995-1000 (2006).
19. A. S. Gajadhar, E. Bogdanovic, D. M. Muñoz, A. Guha, In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy. Mol. Cancer Res. 10, 428-440 (2012).
20. C. Halle, M. Lando, K. Sundfør, G. B. Kristensen, R. Holm, H. Lyng, Phosphorylation of EGFR measured with in situ proximity ligation assay: Relationship to EGFR protein level and gene dosage in cervical cancer. Radiother. Oncol. 101, 152-157 (2011).
21. T. C. Chen, Y. W. Liu, Y. H. Huang, Y. C. Yeh, T. Y. Chou, Y. C. Wu, C. C. Wu, Y. R. Chen, H. C. Cheng, P. J. Lu, J. M. Lai, C. Y. Huang, Protein phosphorylation profiling using an in situ proximity ligation assay: Phosphorylation of AURKA-elicited EGFR-Thr654 and EGFR-Ser1046 in lung cancer cells. PLOS One 8, e55657 (2013).
22. T. Mukohara, J. A. Engelman, N. H. Hanna, B. Y. Yeap, S. Kobayashi, N. Lindeman, B. Halmos, J. Pearlberg, Z. Tsuchihashi, L. C. Cantley, D. G. Tenen, B. E. Johnson, P. A. Jänne, Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97, 1185-1194 (2005).
23. A. G. Batzer, D. Rotin, J. M. Ureña, E. Y. Skolnik, J. Schlessinger, Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol. Cell. Biol. 14, 5192-5201 (1994).
24. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, B. Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, D. Kupfer, R. Wilson, M. Kris, H. Varmus, EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101, 13306-13311 (2004).
25. T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto, B. W. Brannigan, P. L. Harris, S. M. Haserlat, J. G. Supko, F. G. Haluska, D. N. Louis, D. C. Christiani, J. Settleman, D. A. Haber, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl. J. Med. 350, 2129-2139 (2004).
26. L. Song, M. A. Smith, P. Doshi, K. Sasser, W. Fulp, S. Altiok, E. B. Haura, Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer. J. Thorac. Oncol. 9, 974-982 (2014).
27. S. C. Tseng, M. J. Jarvinen, W. G. Nelson, J. W. Huang, J. Woodcock-Mitchell, T. T. Sun, Correlation of specific keratins with different types of epithelial differentiation: Monoclonal antibody studies. Cell 30, 361-372 (1982).
28. M. Hidalgo, F. Amant, A. V. Biankin, E. Budinská, A. T. Byrne, C. Caldas, R. B. Clarke, S. De Jong, J. Jonkers, G. M. Mælandsmo, S. Roman-Roman, J. Seoane, L. Trusolino, A. Villanueva, Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4, 998-1013 (2014).
29. R. Krumbach, J. Schüler, M. Hofmann, T. Giesemann, H. H. Fiebig, T. Beckers, Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: Activation of MET as one mechanism for drug resistance. Eur. J. Cancer 47, 1231-1243 (2011).
30. A. Dimou, S. Agarwal, V. Anagnostou, H. Viray, S. Christensen, B. Gould Rothberg, V. Zolota, K. Syrigos, D. L. Rimm, Standardization of epidermal growth factor receptor (EGFR) measurement by quantitative immunofluorescence and impact on antibodybased mutation detection in non-small cell lung cancer. Am. J. Pathol. 179, 580-589 (2011).
31. S. Kaseda, M. Ueda, S. Ozawa, T. Ishihara, O. Abe, N. Shimizu, Expression of epidermal growth factor receptors in four histologic cell types of lung cancer. J. Surg. Oncol. 42, 16-20 (1989).
32. A. M. Moore, L. H. Einhorn, D. Estes, R. Govindan, J. Axelson, J. Vinson, T. E. Breen, M. Yu, N. H. Hanna, Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: A Hoosier Oncology Group phase II trial. Lung Cancer 52, 93-97 (2006).
33. M. E. Sharafinski, R. L. Ferris, S. Ferrone, J. R. Grandis, Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck. Head Neck 32, 1412-1421 (2010).
34. D. P. Hughes, D. G. Thomas, T. J. Giordano, L. H. Baker, K. T. McDonagh, Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 64, 2047-2053 (2004).
35. T. O. Nielsen, F. D. Hsu, J. X. O'Connell, C. B. Gilks, P. H. Sorensen, S. Linn, R. B. West, C. L. Liu, D. Botstein, P. O. Brown, M. Van De Rijn, Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am. J. Pathol. 163, 1449-1456 (2003).
36. B. Boone, K. Jacobs, L. Ferdinande, J. Taildeman, J. Lambert, M. Peeters, M. Bracke, P. Pauwels, L. Brochez, EGFR in melanoma: Clinical significance and potential therapeutic target. J. Cutan. Pathol. 38, 492-502 (2011).
37. V. N. Ivanov, T. K. Hei, Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: A role of suppression of the PI3K-AKT pathway. Oncogene 24, 616-626 (2005).
38. M. H. Cohen, H. Chen, S. Shord, C. Fuchs, K. He, H. Zhao, S. Sickafuse, P. Keegan, R. Pazdur, Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist 18, 460-466 (2013).
39. G. Improta, A. Zupa, H. Fillmore, J. Deng, M. Aieta, P. Musto, L. A. Liotta, W. Broaddus, E. F. Petricoin III, J. D. Wulfkuhle, Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. J. Proteome Res. 10, 3089-3097 (2011).
40. C. Q. Zhu, G. Da Cunha Santos, K. Ding, A. Sakurada, J. C. Cutz, N. Liu, T. Zhang, P. Marrano, M. Whitehead, J. A. Squire, S. Kamel-Reid, L. Seymour, F. A. Shepherd, M. S. Tsao; National Cancer Institute of Canada Clinical Trials Group Study BR.21, Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J. Clin. Oncol. 26, 4268-4275 (2008).
41. C. Ferté, B. Besse, E. Dansin, F. Parent, M. P. Buisine, M. C. Copin, N. Penel, J. C. Soria, Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ann. Oncol. 21, 1385-1387 (2010).
42. C. R. Chong, P. A. Jänne, The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat. Med. 19, 1389-1400 (2013).
43. L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
44. A. C. Wolff, M. E. Hammond, D. G. Hicks, M. Dowsett, L. M. McShane, K. H. Allison, D. C. Allred, J. M. Bartlett, M. Bilous, P. Fitzgibbons, W. Hanna, R. B. Jenkins, P. B. Mangu, S. Paik, E. A. Perez, M. F. Press, P. A. Spears, G. H. Vance, G. Viale, D. F. Hayes; American Society of Clinical Oncology, College of American Pathologists, Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J. Clin. Oncol. 31, 3997-4013 (2013).
45. J. Qi, M. A. McTigue, A. Rogers, E. Lifshits, J. G. Christensen, P. A. Jänne, J. A. Engelman, Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 71, 1081-1091 (2011).
46. L. Lin, S. Asthana, E. Chan, S. Bandyopadhyay, M. M. Martins, V. Olivas, J. J. Yan, L. Pham, M. M. Wang, G. Bollag, D. B. Solit, E. A. Collisson, C. M. Rudin, B. S. Taylor, T. G. Bivona, Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl. Acad. Sci. U. S. A. 111, E748-E757 (2014).
47. J. Tanizaki, I. Okamoto, T. Okabe, K. Sakai, K. Tanaka, H. Hayashi, H. Kaneda, K. Takezawa, K. Kuwata, H. Yamaguchi, E. Hatashita, K. Nishio, K. Nakagawa, Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin. Cancer Res. 18, 6219-6226 (2012).
48. R. Katayama, A. T. Shaw, T. M. Khan, M. Mino-Kenudson, B. J. Solomon, B. Halmos, N. A. Jessop, J. C. Wain, A. T. Yeo, C. Benes, L. Drew, J. C. Saeh, K. Crosby, L. V. Sequist, A. J. Iafrate, J. A. Engelman, Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci. Transl. Med. 4, 120ra17 (2012).
49. P. R. Gavine, L. Mooney, E. Kilgour, A. P. Thomas, K. Al-Kadhimi, S. Beck, C. Rooney, T. Coleman, D. Baker, M. J. Mellor, A. N. Brooks, T. Klinowska, AZD4547: An orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72, 2045-2056 (2012).
50. D. R. Spigel, T. J. Ervin, R. A. Ramlau, D. B. Daniel, J. H. Goldschmidt Jr., G. R. Blumenschein Jr., M. J. Krzakowski, G. Robinet, B. Godbert, F. Barlesi, R. Govindan, T. Patel, S. V. Orlov, M. S. Wertheim, W. Yu, J. Zha, R. L. Yauch, P. H. Patel, S. C. Phan, A. C. Peterson, Randomized phase II trial of onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 31, 4105-4114 (2013).
51. K. J. Leuchowius, C. M. Clausson, K. Grannas, Y. Erbilgin, J. Botling, A. Zieba, U. Landegren, O. Söderberg, Parallel visualization of multiple protein complexes in individual cells in tumor tissue. Mol. Cell. Proteomics 12, 1563-1571 (2013).
52. J. M. Kreahling, P. Foroutan, D. Reed, G. Martinez, T. Razabdouski, M. M. Bui, M. Raghavan, D. Letson, R. J. Gillies, S. Altiok, Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLOS One 8, e57523 (2013).